open access

Vol 7, No 2 (2016)
Review paper
Published online: 2016-11-09
Get Citation

The highlights of the lymphoid malignancies on the Annual Meeting of the American Society of Clinical Oncology 2016

Ewa Kalinka-Warzocha
DOI: 10.5603/Hem.2016.0011
·
Hematologia 2016;7(2):117-127.

open access

Vol 7, No 2 (2016)
REVIEW ARTICLES
Published online: 2016-11-09

Abstract

This paper presents the most interesting, according to the author’s opinion, trial results presented at the American Society of Clinical Oncology Annual Meeting in 2016. Many study results were presented, most of them important for diagnostics, treatment and prognosis of patients with diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and Hodgkin lymphoma and others.

Abstract

This paper presents the most interesting, according to the author’s opinion, trial results presented at the American Society of Clinical Oncology Annual Meeting in 2016. Many study results were presented, most of them important for diagnostics, treatment and prognosis of patients with diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and Hodgkin lymphoma and others.

Get Citation

Keywords

lymphoma, treatment, prognostic factors

About this article
Title

The highlights of the lymphoid malignancies on the Annual Meeting of the American Society of Clinical Oncology 2016

Journal

Hematology in Clinical Practice

Issue

Vol 7, No 2 (2016)

Article type

Review paper

Pages

117-127

Published online

2016-11-09

DOI

10.5603/Hem.2016.0011

Bibliographic record

Hematologia 2016;7(2):117-127.

Keywords

lymphoma
treatment
prognostic factors

Authors

Ewa Kalinka-Warzocha

References (15)
  1. Witzig TE, Tobinai K, Rigacci L, et al. PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2016; 34(supl.): abstrakt 7506.
  2. Lugtenburg P, et al. de Nully Brown P., van der Holt B. Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: results from a HOVON-Nordic Lymphoma Group study. J Clin Oncol. 2016; 34(supl.): abstrakt 7504.
  3. Kurtz DM, Scherer F, Newman AM, et al. Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics. J Clin Oncol. 2016; 34(supl.): abstrakt 7511.
  4. Crump M, Neelapu S, Farooq U, et al. Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study. Clinical Lymphoma Myeloma and Leukemia. 2016; 34((supl.)): abstrakt 7516.
  5. Mahale P, Turturro F, et al. Effect of antiviral therapy on overall survival in hepatitis c virus-infected patients with diffuse large B-cell lymphoma. J Clin Oncol. 2016; 34(supl.): abstrakt 7540.
  6. Rubenstein L, Fraser E, Formaker P, et al. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. J Clin Oncol. 2016; 34(supl.): abstrakt 7502.
  7. Scott DW, Abrisqueta P, Wright G, et al. Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J Clin Oncol. 2016; 34(supl.): abstrakt 7510.
  8. Rummel M, Knauf W, Goerner M, et al. Two years ritu - ximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016; 34(supl.): abstrakt 7503.
  9. Evens AM, Hong F, Habermann TM. Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): a randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). J Clin Oncol. 2016; 34(supl.): abstrakt 7507.
  10. Trumper LH, Wulf G, Ziepert M, et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT-2 phase III trial. J Clin Oncol. 2016; 34(supl.): abstrakt 7500.
  11. Mounier N, Anthony S, Busson R. Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): an analysis of twelve Collaborative Lymphoma Study Association (LYSA) trials, the Simonal Study. J Clin Oncol. 2016; 34(supl.): abstrakt 7518.
  12. Park SI, Olajide OA, Reddy NM. A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma. J Clin Oncol. 2016; 34(supl.): abstrakt 7508.
  13. Casasnovas RO, Kanoun S, Tal I, et al. Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. J Clin Oncol. 2016; 34(supl.): abstrakt 7509.
  14. Younes A, Santoro A, Zinzani PL. Checkmate 205: nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) — a phase 2 study. J Clin Oncol. 2016; 34(supl.): abstrakt 7535.
  15. Lesokhin AM, Ansell SM, Armand P, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015; 372(4): 311–319.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.